CDR-Life is a clinical-stage biotechnology company focused on transforming the treatment of cancer and autoimmune diseases through its proprietary T cell engager (TCE) platform, M-gager®. The company develops highly selective therapies designed to harness the power of the immune system, targeting both conventional tumor antigens and previously inaccessible or difficult-to-treat targets. On its website, CDR-Life states that it has generated six novel development candidates, with two already advanced to being tested in patients.
CDR-Life positions the M-gager® platform as an antibody-derived, highly targeted approach intended to deliver TCEs against challenging but 'clean' targets, aiming to improve precision, speed, and efficiency from discovery through scalable production. Public materials also describe CDR-Life’s work advancing programs for solid cancers and autoimmune diseases, including a first oncology program entered into clinical trials, and ongoing collaboration activities with partners such as Boehringer Ingelheim.
